<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269515</url>
  </required_header>
  <id_info>
    <org_study_id>OUSCOX2</org_study_id>
    <nct_id>NCT01269515</nct_id>
  </id_info>
  <brief_title>Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients</brief_title>
  <acronym>OUSCOX2</acronym>
  <official_title>Optional Immunomodulating Therapy and Improved Vaccination Responses by Adjuvant Administration of a Cyclooxygenase Type 2 Inhibitor in Antiretroviral naïve HIV-infected Patients and Patients on ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dag Kvale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic immune activation is a central feature of HIV-infection, and the degree of activated&#xD;
      T-cells is a better predictor of disease progression and mortality than plasma viral load.&#xD;
      The study hypothesis is that the anti-inflammatory substance etoricoxib will dampen chronic&#xD;
      immune activation and improve the effect of T-cell dependent vaccines in HIV-1 infected&#xD;
      patients.&#xD;
&#xD;
      The aim of the present study is to explore the efficacy of the study drug on markers of&#xD;
      immune activation and vaccine responses, as well as safety of the study drug, in HIV-infected&#xD;
      patients not receiving antiretroviral therapy and in patients on long-term effective ART who&#xD;
      had CD4 counts &lt; 500.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current trial was based on our observations that augmented levels of cyclic adenosine&#xD;
      monophosphate (cAMP) contribute to the T cell dysfunction in HIV-infected patients. In T&#xD;
      cells, cAMP triggers a protein kinase A (PKA) - Csk - Lck inhibitory pathway that inhibits&#xD;
      the proximal T cell receptor (TCR) signaling events. This mechanism may also be involved in&#xD;
      the inhibitory function of regulatory T cells.&#xD;
&#xD;
      The investigators have hypothesized that elevated levels of cAMP in T cells from HIV-infected&#xD;
      individuals result from increased production of prostaglandin E2 (PGE2) following&#xD;
      activation-induced expression of cyclooxygenase type 2 (COX-2) in lymphoid tissues. Although&#xD;
      the investigators have identified even COX-2 positive T cells in HIV-infected individuals,&#xD;
      activated monocytes may be the major source of PGE2; high levels of COX-2 are produced de&#xD;
      novo after a number of stimuli, particularly lipopolysaccharide (LPS). Circulating LPS is&#xD;
      indeed increased in untreated chronic HIV infection due to enhanced translocation of&#xD;
      microbial material and correlates to chronic immune activation and disease progression.&#xD;
&#xD;
      In three preceding clinical explorative trials, the investigators have demonstrated that&#xD;
      COX-2 inhibition by COX-2 inhibitors (COX-2i) improves the immune functions of HIV patients,&#xD;
      the first two studies included patients on antiretroviral treatment (ART). In the third trial&#xD;
      the investigators also showed for the first time that treatment with a COX-2i was able to&#xD;
      downregulate chronic immune activation and improve T cell functions (efficacy of T&#xD;
      cell-dependent vaccine) in asymptomatic HIV-infected patients who did not use ART. In these&#xD;
      patients, chronic immune activation was dampened as demonstrated; CD38 density on CD8+ T&#xD;
      cells (primary endpoint) decreased by 24% by study week 12. This reduction could be&#xD;
      extrapolated to a possible improvement of CD4+ T cell loss with 30 CD4 cells per ul per year&#xD;
      with an approximate mean CD4 loss of 60 per ul per year. These data founded the basis for&#xD;
      further support to this study through the GLOBVAC call program under the Norwegian Research&#xD;
      Council (granted application for the current study).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in progression markers and vaccine responses within and between ART groups</measure>
    <time_frame>After 6 months</time_frame>
    <description>Changes in CD38 density (CD38 molecules per CD38+CD8+CD3+ T cells) and in humoral and cellular immune responses to study-specific vaccines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>During the 6 months study period</time_frame>
    <description>Reductions of etoricoxib dose or stop of drug, adverse events including cardiovascular events, blood pressure, clinical chemistry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HIV Gag CD8+ T cell responses within and between ART groups</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in HIV Gag CD8+ T cell responses within and between ART groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma markers of inflammation, coagulation and tryptophan metabolism within and between ART groups</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in plasma markers of inflammation, coagulation and tryptophan metabolism</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg qd for 25 weeks ART-</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg qd for 2 weeks ART-</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control ART-</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg qd for 25 weeks ART+</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg qd for 2 weeks ART+</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control ART+</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>90 mg QD</description>
    <arm_group_label>Etoricoxib 90 mg qd for 2 weeks ART+</arm_group_label>
    <arm_group_label>Etoricoxib 90 mg qd for 2 weeks ART-</arm_group_label>
    <arm_group_label>Etoricoxib 90 mg qd for 25 weeks ART+</arm_group_label>
    <arm_group_label>Etoricoxib 90 mg qd for 25 weeks ART-</arm_group_label>
    <other_name>Arcoxia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ART- group: Confirmed diagnosis of HIV infection &lt; 8 years prestudy&#xD;
&#xD;
          -  no HIV-related clinical manifestations including acute HIV infection&#xD;
&#xD;
          -  no current indication or use for antiretroviral treatment&#xD;
&#xD;
          -  CD4+ count &gt; 350 x 10^6 /l&#xD;
&#xD;
          -  HIV RNA &gt; 2000 copies/ml&#xD;
&#xD;
        ART+ group: Confirmed diagnosis of HIV infection&#xD;
&#xD;
          -  no HIV-related clinical manifestations including acute HIV infection&#xD;
&#xD;
          -  On stabile effective antiretroviral treatment (HIV RNA &lt;50 copies/ml)&#xD;
&#xD;
          -  CD4+ count &lt; 500 x 10^6 /l&#xD;
&#xD;
          -  HIV RNA &gt; 2000 copies/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concomitant or sporadic use of NSAID, corticosteroids or other immune modulating&#xD;
             therapies including interferon-alpha&#xD;
&#xD;
          -  cholesterol &gt; 7 M&#xD;
&#xD;
          -  under treatment for hypertension or antihypertensive treatment indicated at inclusion&#xD;
&#xD;
          -  cardiovascular events or stroke in parents, siblings or off-springs occurring &lt; 55&#xD;
             years of age&#xD;
&#xD;
          -  elevated serum creatinine&#xD;
&#xD;
          -  diabetes type I or II&#xD;
&#xD;
          -  known hypersensitivity for etoricoxib, capsule substances or sulphonamides&#xD;
&#xD;
          -  active peptic ulcer or gastrointestinal haemorrhage&#xD;
&#xD;
          -  history of asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or&#xD;
             other allergic reactions after taking acetyl salicylic acid or NSAID including COX-2&#xD;
             inhibitors&#xD;
&#xD;
          -  pregnancy or insufficient birth control for females&#xD;
&#xD;
          -  breastfeeding&#xD;
&#xD;
          -  seriously deranged liver function&#xD;
&#xD;
          -  creatine clearance &lt; 30 ml/min&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  heart failure (NYHA II-IV)&#xD;
&#xD;
          -  established ischaemic heart disease, peripheral arteriosclerosis and/or&#xD;
             cerebrovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Kvale, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Biotechnology Centre, University of Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Prebensen C, Trøseid M, Ueland T, Dahm A, Sandset PM, Aaberge I, Waalen K, Dyrhol-Riise AM, Taskén K, Kvale D. Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. PLoS One. 2017 May 2;12(5):e0176527. doi: 10.1371/journal.pone.0176527. eCollection 2017.</citation>
    <PMID>28464042</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Dag Kvale</investigator_full_name>
    <investigator_title>Professor, Senior consultant</investigator_title>
  </responsible_party>
  <keyword>Cox-2 inhibitor</keyword>
  <keyword>HIV</keyword>
  <keyword>immune activation</keyword>
  <keyword>immune modulating</keyword>
  <keyword>progression markers</keyword>
  <keyword>vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

